Skip to main
SRZN

Surrozen (SRZN) Stock Forecast & Price Target

Surrozen (SRZN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Surrozen Inc. is poised for growth as it approaches the clinical initiation for its lead product candidate SZN-8141, with an increased modeled factor of wet AMD patients seeking novel treatments, now estimated at 25%. Additionally, a collaboration with Boehringer Ingelheim has resulted in a significant $5 million milestone payment for its partnered program SZN-413, underscoring the validation of Surrozen's Wnt asset development. The company’s success in preclinical studies, particularly pertaining to SZN-413, complements the promising prospects for its wholly-owned candidates, SZN-8141 and SZN-8143, indicating strong potential within the evolving therapeutic landscape for retinal diseases.

Bears say

Surrozen Inc's stock faces significant risks due to its reliance on successful capital raises, which may not occur on favorable terms, potentially leading to adverse effects on stock performance. Key concerns include the possibility that its developmental candidates may not meet peak commercial revenue expectations due to limitations in market size, penetration rates, or pricing, alongside the need for adequate capital resources to sustain operations. Additionally, the company’s lead candidate, SZN-8141, may face unexpected toxicity in early studies or potential failures in related studies by partners such as Merck, which could negatively impact the perception of the entire Wnt agonist class for retinal diseases.

Surrozen (SRZN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surrozen (SRZN) Forecast

Analysts have given Surrozen (SRZN) a Buy based on their latest research and market trends.

According to 2 analysts, Surrozen (SRZN) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surrozen (SRZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.